<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02652065</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL15_0425</org_study_id>
    <nct_id>NCT02652065</nct_id>
  </id_info>
  <brief_title>Cutaneous Microcirculation and Nervous Sensitivity in Psoriasis</brief_title>
  <acronym>MicroPso</acronym>
  <official_title>Cutaneous Microcirculation and Nervous Sensitivity in Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psoriasis is a chronic inflammatory cutaneous disease, affecting 3% of the French population.
      Among psoriatic patients, 80% feel pain or cutaneous discomfort related to their pathology.

      Neurogenic inflammation's role in psoriasis has recently been put forward by a study showing
      that TRPV1 ion channels are necessary to establish psoriasiform inflammation in mice.

      The investigators hypothesize that there is a link between cutaneous sensory neuropathies and
      altered cutaneous microcirculation during psoriasis.

      In order to test this hypothesis, local vasodilators will be delivered to patients by
      iontophoresis and their skin blood flow in response to these molecules will be followed by
      laser Doppler recordings. Two recordings will be performed for each patient, both on a
      psoriasis plaque and on uninvolved skin, in order for the patient to be his own internal
      control.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2016</start_date>
  <completion_date type="Anticipated">February 7, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 7, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>skin blood flow variation</measure>
    <time_frame>at the latest 3 months after inclusion</time_frame>
    <description>Skin blood flow variation on healthy skin and on psoriasis plaque will be measured by Laser Doppler in response to iontophoretic delivery of vasodilator substances (sodium nitroprussiate and acetylcholine) and ppi water. Skin blood flow will be recorded during 2 minutes before iontophoresis, and during 30 minutes following iontophoretic delivery of vasodilators.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensory detection threshold</measure>
    <time_frame>at the latest 3 months after inclusion</time_frame>
    <description>Increasing size of Von Frey filaments will be placed onto patients' skin to assess sensory detection threshold.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential discomfort sensation thresholds</measure>
    <time_frame>at the latest 3 months after inclusion</time_frame>
    <description>Increasing size of Von Frey filaments will be placed onto patients' skin to assess potential discomfort sensation threshold.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heat sensitivity</measure>
    <time_frame>at the latest 3 months after inclusion</time_frame>
    <description>Heat sensitivity will be assessed using hot (50°C) and cold (4°C) water</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Healthy skin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on healthy skin.
The skin blood flow in response to these molecules will be followed by laser Doppler recordings.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psoriasis plaque</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on a psoriasis plaque (on the patient's back).
The skin blood flow in response to these molecules will be followed by laser Doppler recordings.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acetylcholine iontophoresis</intervention_name>
    <description>Acetylcholine will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).</description>
    <arm_group_label>Healthy skin</arm_group_label>
    <arm_group_label>Psoriasis plaque</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sodium Nitroprussiate iontophoresis</intervention_name>
    <description>Sodium Nitroprussiate will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).</description>
    <arm_group_label>Healthy skin</arm_group_label>
    <arm_group_label>Psoriasis plaque</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ppi water iontophoresis</intervention_name>
    <description>ppi water will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).</description>
    <arm_group_label>Healthy skin</arm_group_label>
    <arm_group_label>Psoriasis plaque</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laser Doppler recording</intervention_name>
    <description>Skin blood flow will be recorded by laser Doppler during 2 minutes before iontophoresis, and during 30 minutes following iontophoretic delivery of vasodilators.</description>
    <arm_group_label>Healthy skin</arm_group_label>
    <arm_group_label>Psoriasis plaque</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type I psoriasis

          -  Psoriasis plaques on the patient's back

        Exclusion Criteria:

          -  BMI &gt; 25

          -  Diabetic patient

          -  Arteriovenous disease history

          -  Ongoing anti-inflammatory treatment

          -  Major cardiovascular history (&lt;3 months)

          -  Hypertension

          -  Topical treatment on the back skin (&lt;7 days)

          -  Systemic treatment (steroids, methotrexate, retinoids, cyclosporine) or phototherapy
             (&lt;1 month)

          -  Pregnant women

          -  Subject within exclusion period following a previous or ongoing biomedical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Denis JULLIEN, MD, PhD</last_name>
    <phone>+33 472 117 211</phone>
    <email>denis.jullien@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne-Sophie BOISGARD</last_name>
    <phone>+33 437 652 911</phone>
    <email>anne-sophie.boisgard@ibcp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot - Service de Dermatologie et Vénéréologie</name>
      <address>
        <city>LYON cedex 03</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis JULLIEN, MD, PhD</last_name>
      <phone>+33 472 117 211</phone>
      <email>denis.jullien@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Denis JULLIEN, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2016</study_first_submitted>
  <study_first_submitted_qc>January 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2016</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Microcirculation</keyword>
  <keyword>TRPV1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcholine</mesh_term>
    <mesh_term>Vasodilator Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

